AQR Capital Management LLC Purchases Shares of 88,373 RAPT Therapeutics, Inc. (NASDAQ:RAPT)

AQR Capital Management LLC acquired a new stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) in the second quarter, Holdings Channel.com reports. The firm acquired 88,373 shares of the company’s stock, valued at approximately $270,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in RAPT Therapeutics during the first quarter worth about $97,000. XTX Topco Ltd purchased a new stake in RAPT Therapeutics in the 2nd quarter worth approximately $108,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of RAPT Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares during the period. EntryPoint Capital LLC purchased a new position in shares of RAPT Therapeutics during the 1st quarter valued at approximately $161,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of RAPT Therapeutics by 66.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after purchasing an additional 33,692 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 3.4 %

Shares of NASDAQ RAPT opened at $1.69 on Friday. The firm has a market cap of $58.99 million, a price-to-earnings ratio of -0.55 and a beta of 0.33. The company’s 50-day simple moving average is $2.03 and its 200-day simple moving average is $3.90. RAPT Therapeutics, Inc. has a 52-week low of $1.66 and a 52-week high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. Equities research analysts anticipate that RAPT Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. UBS Group lowered their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $18.17.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.